New PET scan tracer could sharpen cancer detection
NCT ID NCT05749289
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new radioactive tracer called Al18F-octreotide for PET/CT scans in people with suspected or confirmed SSTR-positive tumors. The goal is to see if this tracer can more accurately detect these tumors. About 400 participants will receive an injection of the tracer before their scan. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Al18F-octreotide (a radioactive tracer injected before PET/CT scans)
- What this could lead to
- If successful, this could provide a more accurate imaging method to detect and diagnose SSTR-positive tumors, helping guide treatment decisions.
- What could go wrong
- This is an early-phase diagnostic study, so the tracer may not prove more accurate than existing methods. Results may not apply to all tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SSTR POSITIVE TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Chao Yang, 100021, China